{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T14:16:15Z","timestamp":1789049775627,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40263-026-01324-6","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T10:59:40Z","timestamp":1784199580000},"page":"1313-1316","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Psychedelics for Patients Experiencing Existential Distress, Anxiety or Depression in Palliative Care"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4409-0795","authenticated-orcid":false,"given":"Peter","family":"Tanuseputro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Docherty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melanie","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Gearin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"issue":"2","key":"1324_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1124\/pr.115.011478","volume":"68","author":"DE Nichols","year":"2016","unstructured":"Nichols DE. Psychedelics. Pharmacol Rev. 2016;68(2):264\u2013355.","journal-title":"Pharmacol Rev"},{"issue":"10","key":"1324_CR2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0293349","volume":"18","author":"J Evans","year":"2023","unstructured":"Evans J, Robinson OC, Argyri EK, Suseelan S, Murphy-Beiner A, McAlpine R, et al. Extended difficulties following the use of psychedelic drugs: a mixed methods study. PLoS ONE. 2023;18(10):e0293349.","journal-title":"PLoS ONE"},{"issue":"6","key":"1324_CR3","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1177\/0269881108093587","volume":"22","author":"MW Johnson","year":"2008","unstructured":"Johnson MW, Richards WA, Griffiths RR. Human hallucinogen research: guidelines for safety. J Psychopharmacol. 2008;22(6):603\u201320.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"1324_CR4","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1038\/s41386-019-0324-9","volume":"44","author":"MK Madsen","year":"2019","unstructured":"Madsen MK, Fisher PM, Burmester D, Dyssegaard A, Stenbaek DS, Kristiansen S, et al. Psychedelic effects of psilocybin correlate with serotonin 2A receptor occupancy and plasma psilocin levels. Neuropsychopharmacology. 2019;44(7):1328\u201334.","journal-title":"Neuropsychopharmacology"},{"issue":"1","key":"1324_CR5","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","volume":"68","author":"CS Grob","year":"2011","unstructured":"Grob CS, Danforth AL, Chopra GS, Hagerty M, McKay CR, Halberstad AL, et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch Gen Psychiatry. 2011;68(1):71\u20138.","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"1324_CR6","doi-asserted-by":"publisher","first-page":"e252853","DOI":"10.1001\/jamanetworkopen.2025.2853","volume":"8","author":"J Matsukubo","year":"2025","unstructured":"Matsukubo J, Dickson S, Xiao J, Friesen EL, Solmi M, Fiedorowicz JG, et al. Psilocybin dispensaries and online health claims in Canada. JAMA Netw Open. 2025;8(4):e252853.","journal-title":"JAMA Netw Open"},{"issue":"12","key":"1324_CR7","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1177\/0269881116675513","volume":"30","author":"RR Griffiths","year":"2016","unstructured":"Griffiths RR, Johnson MW, Carducci MA, Umbricht A, Richards WA, Richards BD, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181\u201397.","journal-title":"J Psychopharmacol"},{"issue":"12","key":"1324_CR8","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1177\/0269881116675512","volume":"30","author":"S Ross","year":"2016","unstructured":"Ross S, Bossis A, Guss J, Agin-Liebes G, Malone T, Cohen B, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: A randomized controlled trial. J Psychopharmacol. 2016;30(12):1165\u201380.","journal-title":"J Psychopharmacol"},{"issue":"7","key":"1324_CR9","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","volume":"202","author":"P Gasser","year":"2014","unstructured":"Gasser P, Holstein D, Michel Y, Doblin R, Yazar-Klosinski B, Passie T, et al. Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases. J Nerv Ment Dis. 2014;202(7):513\u201320.","journal-title":"J Nerv Ment Dis"},{"key":"1324_CR10","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.genhosppsych.2025.08.001","volume":"96","author":"ML Ross","year":"2025","unstructured":"Ross ML, Iyer R, Williams ML, Boughey M, O\u2019Callaghan C, Hiscock R, et al. Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: A phase 2b randomized controlled trial. Gen Hosp Psychiatry. 2025;96:322\u201331.","journal-title":"Gen Hosp Psychiatry"},{"issue":"2","key":"1324_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1177\/0269881119897615","volume":"34","author":"GI Agin-Liebes","year":"2020","unstructured":"Agin-Liebes GI, Malone T, Yalch MM, Mennenga SE, Pont\u00e9 KL, Guss J, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. J Psychopharmacol. 2020;34(2):155\u201366.","journal-title":"J Psychopharmacol"},{"issue":"9","key":"1324_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.9305","volume":"12","author":"S Federico","year":"2024","unstructured":"Federico S, Geo M, Entela M, Bachmann S, Elisa R, Silvio C, et al. Psychedelic-assisted therapy for palliative care within a home treatment setting: A case report. Clin Case Rep. 2024;12(9):e9305.","journal-title":"Clin Case Rep."},{"issue":"11","key":"1324_CR13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.46747\/cfp.6811823","volume":"68","author":"R Patchett-Marble","year":"2022","unstructured":"Patchett-Marble R, O\u2019Sullivan S, Tadwalkar S, Hapke E. Psilocybin mushrooms for psychological and existential distress: Treatment for a patient with palliative lung cancer. Can Fam Physician. 2022;68(11):823\u20137.","journal-title":"Can Fam Physician"},{"issue":"1","key":"1324_CR14","doi-asserted-by":"publisher","first-page":"30","DOI":"10.26443\/ijwpc.v10i1.373","volume":"10","author":"H Farzin","year":"2023","unstructured":"Farzin H. Healing at death\u2019s door: one patient\u2019s mystical experience with psilocybin. Int J Whole Person Care. 2023;10(1):30\u20132.","journal-title":"Int J Whole Person Care"},{"issue":"9","key":"1324_CR15","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1089\/jpm.2024.0066","volume":"27","author":"MP Clark","year":"2024","unstructured":"Clark MP. Psilocybin: medicine for my soul. Relief from emotional and spiritual pain as a hospice nurse diagnosed with cancer. J Palliat Med. 2024;27(9):1272\u20133.","journal-title":"J Palliat Med"},{"issue":"4","key":"1324_CR16","first-page":"557","volume":"28","author":"JF Stephan","year":"2025","unstructured":"Stephan JF, Karam S. Psilocybin-assisted therapy for brain cancer related existential distress: a case-report. J Palliat Med. 2025;28(4):557\u20139.","journal-title":"J Palliat Med"},{"issue":"3","key":"1324_CR17","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jpainsymman.2023.06.006","volume":"66","author":"BR Lewis","year":"2023","unstructured":"Lewis BR, Garland EL, Byrne K, Durns T, Hendrick J, Beck A, et al. HOPE: A pilot study of psilocybin enhanced group psychotherapy in patients with cancer. J Pain and Sympt Manage. 2023;66(3):258\u201369.","journal-title":"J Pain and Sympt Manage."},{"key":"1324_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100538","author":"B Anderson","year":"2020","unstructured":"Anderson B, Danforth A, Daroff PR, Stauffer C, Ekman E, Agin-Liebes G, et al. Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study. eClinicalMedicine. 2020. https:\/\/doi.org\/10.1016\/j.eclinm.2020.100538.","journal-title":"eClinicalMedicine"},{"issue":"7","key":"1324_CR19","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/cncr.35010","volume":"130","author":"M Agrawal","year":"2024","unstructured":"Agrawal M, Richards W, Beaussant Y, Shnayder S, Ameli R, Roddy K, et al. Psilocybin-assisted group therapy in patients with cancer diagnosed with a major depressive disorder. Cancer. 2024;130(7):1137\u201346.","journal-title":"Cancer"},{"issue":"9","key":"1324_CR20","doi-asserted-by":"publisher","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","volume":"14","author":"SD Muthukumaraswamy","year":"2021","unstructured":"Muthukumaraswamy SD, Forsyth A, Lumley T. Blinding and expectancy confounds in psychedelic randomized controlled trials. Exp Rev Clin Pharmacol. 2021;14(9):1133\u201352.","journal-title":"Exp Rev Clin Pharmacol."},{"issue":"2","key":"1324_CR21","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acsptsci.0c00194","volume":"4","author":"DB Yaden","year":"2021","unstructured":"Yaden DB, Griffiths RR. The subjective effects of psychedelics are necessary for their enduring therapeutic effects. ACS Pharmacol Transl Sci. 2021;4(2):568\u201372.","journal-title":"ACS Pharmacol Transl Sci"},{"key":"1324_CR22","doi-asserted-by":"publisher","first-page":"204512532513810","DOI":"10.1177\/20451253251381074","volume":"15","author":"SD Muthukumaraswamy","year":"2025","unstructured":"Muthukumaraswamy SD, Baggott MJ, Schenberg EE, Repantis D, Wolff M, Forsyth A, et al. Psychedelic-assisted therapy as a complex intervention: Implications for clinical trial design. Ther Adv Psychopharmacol. 2025;15:20451253251381070.","journal-title":"Ther Adv Psychopharmacol."},{"key":"1324_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2026.117010","volume":"359","author":"SP Goldy","year":"2026","unstructured":"Goldy SP, Sepeda ND, Hilbert SN, Bari BA, Garcia-Romeu A, Gukasyan N, et al. Trip sitting or just sitting? Session facilitators substantially influence psychedelic experiences in clinical trials but not in healthy ones. Psychiatry Res. 2026;359:117010.","journal-title":"Psychiatry Res"},{"issue":"2","key":"1324_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/anoc.70012","volume":"36","author":"JA Breau","year":"2025","unstructured":"Breau JA, Gillis-Smith P, Deonauth T. Ketamine integration chaplaincy: A novel spiritual care approach to psychedelic integration. Anthropol Conscious. 2025;36(2):e70012.","journal-title":"Anthropol Conscious"},{"key":"1324_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-026-03913-x","author":"A Gearin","year":"2026","unstructured":"Gearin A, Docherty J, Sun X, Cheung E, Tanuseputro P. Psychedelic therapy and cultural humility. Transl Psychiatry. 2026. https:\/\/doi.org\/10.1038\/s41398-026-03913-x.","journal-title":"Transl Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01324-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-026-01324-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-026-01324-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T13:59:51Z","timestamp":1789048791000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-026-01324-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":25,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1324"],"URL":"https:\/\/doi.org\/10.1007\/s40263-026-01324-6","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors did not receive any specific funding to support this paper.","order":1,"name":"Ethics","label":"Funding","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As this paper is a commentary, it did not seek out any ethics approval.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper did not include any subjects.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This paper represents original work of the authors who all consent to publish.","order":6,"name":"Ethics","label":"Consent to Publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No new data was presented in this commentary.","order":7,"name":"Ethics","label":"Availability of Data and Materials","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors contributed significantly to the commentary ideas. All authors contributed to drafting parts of the manuscript, and all authors reviewed the manuscript and provided critical feedback. All authors have read and approved the final version of the manuscript.","order":8,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}